Skip to main content

toppbild-investerare-1551x278.jpg

Investors

Moberg Pharma’s share is listed on the main list at NASDAQ OMX Stockholm. Moberg Pharma’s goal is to create value and provide attractive shareholder returns through the successful commercialization of its pipeline assets.

 

Aktiekurs 17 Jun 2013 14:30
33.90 kr
1.19 %
  • All pressreleases
  • Regulatory
2024-11-12 | Press release
Moberg Pharma´s Interim report January - September 2024
2024-11-08 | Press release
Moberg Pharma’s Nomination Committee appointed
2024-09-13 | Press release
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Read more »

2024-11-12 | Press release
Moberg Pharma´s Interim report January - September 2024
2024-11-08 | Press release
Moberg Pharma’s Nomination Committee appointed
2024-09-13 | Press release
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Read more press releases »

Interview with CEO Anna Ljung

Link to video from November 12, 2024

Latest report

2024-11-12 Moberg Pharma´s Interim report January - September 2024

Calendar/presentations

Next calendar event: 2024-12-03 Redeye Life Science Day

Contact Investor
relations:

Anna Ljung, CEO
Tel. +46 (0)8 522 307 01
Email: anna.ljung@mobergpharma.se
 

 

Subscribe

Get our latest press releases and reports